Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(40.0%)
N/A
2(40.0%)
Phase 3
1(20.0%)
5Total
Phase 4(2)
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04640649Not ApplicableUnknown

Prediction of Progression of Age-Related Macular Degeneration

Role: collaborator

NCT00690313Phase 4Completed

Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections

Role: lead

NCT01428388Not ApplicableCompleted

Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion

Role: collaborator

NCT00680498Phase 4Completed

Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment

Role: lead

NCT01027611Phase 3Completed

Patient Assessment of Topical Anesthetic Effectiveness for Intravitreal Injections

Role: lead

All 5 trials loaded